MAP2K7 and metastatic melanoma: For BRAF-mutated metastatic melanoma, targeted therapies—such as the BRAF inhibitors dabrafenib, vemurafenib, and encorafenib—are available, which in combination with MEK inhibitors—such as trametinib, cobimetinib, and binimetinib—can help overcome acquired resistance and improve survival and response outcomes [9,10,11,12].